Department of Biomedical Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, 155 Fifth Street, San Francisco, CA 94103, USA.
BPS Bioscience, 6405 Mira Mesa Blvd, Suite 100, San Diego, CA 92121, USA.
Int J Mol Sci. 2024 Jun 9;25(12):6382. doi: 10.3390/ijms25126382.
SARS-CoV-2 S-protein-mediated fusion is thought to involve the interaction of the membrane-distal or N-terminal heptad repeat (NHR) ("HR1") of the cleaved S2 segment of the protein and the membrane-proximal or C-terminal heptad repeat (CHR) ("HR2") regions of the protein. We examined the fusion inhibitory activity of a PEGylated HR2-derived peptide and its palmitoylated derivative using a pseudovirus infection assay. The latter peptide caused a 76% reduction in fusion activity at 10 µM. Our results suggest that small variations in peptide derivatization and differences in the membrane composition of pseudovirus preparations may affect the inhibitory potency of HR2-derived peptides. We suggest that future studies on the inhibition of infectivity of SARS-CoV-2 in both in vitro and in vivo systems consider the need for higher concentrations of peptide inhibitors.
SARS-CoV-2 S 蛋白介导的融合被认为涉及蛋白裂解的 S2 段的膜远端或 N 端七肽重复(NHR)(“HR1”)与蛋白的膜近端或 C 端七肽重复(CHR)(“HR2”)区域的相互作用。我们使用假病毒感染测定法检查了聚乙二醇化 HR2 衍生肽及其棕榈酰化衍生物的融合抑制活性。后者的肽在 10 µM 时使融合活性降低了 76%。我们的结果表明,肽衍生化的微小差异和假病毒制剂的膜组成的差异可能会影响 HR2 衍生肽的抑制效力。我们建议,未来在体外和体内系统中研究 SARS-CoV-2 感染性的抑制作用时,需要考虑更高浓度的肽抑制剂。